12 Stocks That Will Double in 2025

Page 3 of 11

9. Legend Biotech Corporation (NASDAQ:LEGN)

Analyst Upside as of January 28, 2025: 129%

Number of Hedge Fund Holders: 31

Legend Biotech Corporation (NASDAQ:LEGN) is a biotechnology company committed to delivering cutting-edge options for patients across the world. The company was founded as an early-stage cell therapy company in 2014 and is now a global commercial-stage company with several cell therapies in its portfolio. In the third quarter of 2024, its star drug, CARVYKTI, generated net trade sales worth $286 million, representing operational growth of 87.6% year-over-year, and 53.2% sequentially. During the quarter, the company also launched in Switzerland, received China’s NMPA approval for the treatment of fourth-line plus multiple myeloma, and announced plans to launch a cell therapy research and development facility in Philadelphia.

On January 23, Justin Zelin, an analyst at BTIG maintained a buy rating on Legend Biotech Corporation (NASDAQ:LEGN), retaining the price target of $91. Zelin gave a buy rating on the stock because of the company’s strategic partnerships. Specifically, the analyst pointed to its partnership with JNJ in 2024, resulting in prominent year-over-year growth for CARVYKTI. In addition to that, Zelin is particularly optimistic about the plans LEGN has outlined to meet future demand through capacity expansions in 2025. On the same day, analyst firm, Barclays assigned a buy rating to the stock with a price target of $49. Analysts are also bullish on the stock and their median price target represents an upside of 129%.

Page 3 of 11